Cargando…

Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India

Meningococcal disease is highly transmissible, life-threatening and leaves significant sequelae in survivors. Every year, India, which has a plethora of risk factors for meningococcal disease, reports around 3000 endemic cases. However, the overall disease burden and serogroup distribution are unkno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubey, Anand P., Hazarika, Rashna Dass, Abitbol, Veronique, Kolhapure, Shafi, Agrawal, Someya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Meningococcal – Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993054/ https://www.ncbi.nlm.nih.gov/pubmed/35239455 http://dx.doi.org/10.1080/21645515.2022.2026712

Ejemplares similares

Mass gatherings: a review of the scope for meningococcal vaccination in the Indian context
por: Dubey, Anand P, et al.
Publicado: (2021)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Changing patterns of invasive meningococcal disease and future immunization strategies
por: Taha, Muhamed-Kheir, et al.
Publicado: (2023)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
por: Presa, Jessica, et al.
Publicado: (2023)

Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Meningococcal disease within the Gulf Cooperation Council Countries
por: Al Awaidy, Salah, et al.
Publicado: (2023)

Pandemic’s influence on parents’ attitudes and behaviors toward meningococcal vaccination
por: Tan, Litjen (L.J), et al.
Publicado: (2023)

Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam
por: The Nguyen, Phung Nguyen, et al.
Publicado: (2023)

Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: An Asia-Pacific expert group perspective on current epidemiology and vaccination policies
por: Thisyakorn, Usa, et al.
Publicado: (2022)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
por: Robertson, Corwin A., et al.
Publicado: (2023)

A Comprehensive Review of Meningococcal Disease Burden in India
por: Dutta, Ashok Kumar, et al.
Publicado: (2020)

Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis
por: Xu, Juan, et al.
Publicado: (2022)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Meningococcal carriage in the African meningitis belt
Publicado: (2013)

Preventing invasive meningococcal disease in early infancy
por: Presa, Jessica, et al.
Publicado: (2022)

Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico
por: Chacon-Cruz, Enrique, et al.
Publicado: (2022)

Product review on the IMD serogroup B vaccine Bexsero®
por: Deghmane, Ala-Eddine, et al.
Publicado: (2022)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Weil-Olivier, Catherine, et al.
Publicado: (2022)

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
por: Piazza, Franco M., et al.
Publicado: (2021)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
por: Stefanizzi, Pasquale, et al.
Publicado: (2021)

Meningococcal disease serogroup C
por: Dickinson, Félix O, et al.
Publicado: (2012)

Serogroup Y Meningococcal Disease, Colombia
por: Agudelo, Clara Inés, et al.
Publicado: (2008)

The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology
por: Racloz, Vanessa N, et al.
Publicado: (2010)

Serogroup X in Meningococcal Disease, Western Kenya
por: Materu, Sadiki, et al.
Publicado: (2007)

Toward an Improved Meningococcal Serogroup B Assay
por: Poolman, Jan
Publicado: (2018)

The need for vaccination in adults with chronic (noncommunicable) diseases in India – lessons from around the world
por: Vora, Agam, et al.
Publicado: (2022)

Invasive Meningococcal Infection: Analysis of 110 cases from a Tertiary Care Centre in North East India
por: Dass Hazarika, Rashna, et al.
Publicado: (2012)

Serogroup W135 Meningococcal Disease, The Gambia, 2012
por: Hossain, M. Jahangir, et al.
Publicado: (2013)

An Unexpected Fever Post Serogroup B Meningococcal Sepsis
por: Donà, Daniele, et al.
Publicado: (2016)

Meningococcal serogroups and surveillance: a systematic review and survey
por: Peterson, Meagan E, et al.
Publicado: (2019)

Meningococcal serogroup B vaccines: Estimating breadth of coverage
por: Donald, Robert G. K., et al.
Publicado: (2016)

Recent Progress in the Prevention of Serogroup B Meningococcal Disease
por: Feavers, Ian M., et al.
Publicado: (2017)

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
por: Daugla, DM, et al.
Publicado: (2013)

Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: Results from a decision-analysis model
por: Régnier, Stéphane A, et al.
Publicado: (2014)

Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia
por: Mohammed, Hassen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2bmg8ik4snm9mtpl35ef48fs7